Tel Aviv University
Tel Aviv, 6997801, Israel
NCT Number: NCT07364981
The main objective of this randomized controlled trial is to evaluate whether a gaze-contingent feedback task using negative reinforcement can serve as an effective attention-modification procedure and contribute to the treatment of Major Depressive Disorder (MDD).
Trial opening soon.
Get Notified18 year–65 year
All sexes
Interventional
Not applicable
Tel Aviv, 6997801, Israel
This randomized controlled trial uses a gaze-contingent attentional reinforcement task to modify attention allocation patterns to emotional stimuli in participants with Major Depressive Disorder. Specifically, participants will undergo 4 training sessions, during which either negative reinforcement (aversive white noise will be heard when gazing at sad faces) or positive reinforcement (music will be heard when gazing at happy faces) will be used to divert participants' gaze toward happy faces and away from sad faces. Depressive symptoms severity will be assessed before and after training (post-training and 3-month follow up) to examine changes (reduction) in symptom severity from before to after the intervention. Attention allocation will be assessed during training (i.e. online learning) as well as before and after training (i.e. transfer of learning).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receveve gaze-contingent negative-reinforcement feedback according to their viewing patterns, such that when gazing at the target stimuli (i.e., happy faces) the noise will stop.
Participants will receive gaze-contingent music-reward according to their viewing patterns, such that when gazing at the target stimuli (i.e., happy faces) the music will play.
Time frame: Post-treatment (1 week after treatment completion) and 3-month follow up
Change from baseline- the Montgomery Asberg Depression Rating scale is a clinician-administered scale that includes 10 items that measure the severity of depressive symptoms. Each of the 10 items is scored on a 7-point scale (0-6). The total score, ranging from 0 to 60 is used to assess severity.
Time frame: Post-treatment (1 week after treatment completion) and 3-month follow up
Change from baseline- the Patient Health Questionnaire-9 is a nine-question self-report questionnaire to assess the severity of depression based on symptoms over the past two weeks. Each item is scored from 0 (not at all) to 3 (nearly every day). The overal score ranges from 0-27, indicating depression severity.
Time frame: Post-treatment (1 week after treatment completion) and 3-month follow up
Changes from baseline- attention allocation towards the target stimuli (happy faces) compared to the non-target stimuli (sad faces).
Time frame: Post-treatment (1 week after treatment completion) and 3-month follow up
Changes in the Mini-International Neuropsychiatric Interview diagnosis. The M.I.N.I. is a structured diagnostic interview for DSM-5 and ICD-11 psychiatric disorders.
Contact information is provided by the study sponsor or research team.
Tel Aviv University
Other
Gaze Contingent Attentional Reinforcement Treatment of MDD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07728253
Depressive Disorder, Depressive Disorder, Major
Shanghai, China
View Trial DetailsNCT07727005
Depressive Disorder, Depressive Disorder, Major
Munich, Bavaria, Germany
View Trial DetailsNCT07712159
Anxiety Disorders, Depressive Disorder
View Trial DetailsNCT07043738
Behavior, Behavioral Symptoms
View Trial Details